GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BioLineRx BLRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.58

-7.60%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About BioLineRx

Its shares trade under the ticker BLRX. It has been listed since 25 July 2011. In the fiscal year to 31 December 2025, it reported revenue of $1.2m and a net loss of $1.2m. At that date it held total assets of $40.9m and shareholders' equity of $18.2m.

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
25 Jul 2011
Employees
20
Head office
2 HAMAAYAN STREET, MODI-IN, ISRAEL
Incorporated in
L3
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • BioLineRx's GLIX1 targets DNA damage response in glioblastoma and other cancers with oral small molecule therapy.
  • APHEXDA (motixafortide) is in Phase 1 for sickle cell disease and Phase 2b for pancreatic cancer treatment.
  • BL-5010 offers non-surgical skin lesion removal using a pen-like applicator with acidic solution.

Weaknesses

  • BioLineRx has only 20 employees, limiting operational capacity and scalability.
  • The company's clinical trials are in early phases for most products, increasing development risk.
  • BioLineRx is headquartered in Hevel Modi'in, Israel, which may limit global market access.

Opportunities

  • APHEXDA's Phase 3 completion for multiple myeloma opens new market opportunities in oncology.
  • Expanding APHEXDA's Phase 2b trial for pancreatic cancer could attract significant investment.
  • GLIX1's focus on glioblastoma addresses a high unmet medical need in oncology.

Threats

  • BioLineRx's reliance on clinical trial success for APHEXDA and GLIX1 poses high development risk.
  • Competition in oncology therapeutics could impact market share for BioLineRx's pipeline.
  • Regulatory delays in clinical trials may hinder product commercialization timelines.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.